The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Gustafsson, David ^a   Unwin, Robert ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Cardiovascular events; Chronic kidney disease; Congestive heart failure; Hypertension; Metabolic syndrome; Type 2 diabetes mellitus; Urate; Uric acid

Indexed keywords

ALLOPURINOL; ARHALOFENATE; BENZBROMARONE; CANAKINUMAB; COLCHICINE; FEBUXOSTAT; LESINURAD; PROBENECID; PURINE; RDEA 3170; RILONACEPT; SEVELAMER; TOFISOPAM; ULODESINE; UNCLASSIFIED DRUG; URATE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIETARY INTAKE; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PURINE METABOLISM; REVIEW; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPERURICEMIA; MORBIDITY;

EID: 84880926698     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-164     Document Type: Review

References (79)

1. Pathogenesis of Gout. Choi HK, Mount DB, Reginato AM, Ann Intern Med 2005 143 7 499 516 10.7326/0003-4819-143-7-200510040-00009 16204163 (Pubitemid 41379398)
2. Uric acid and cardiovascular risk. Feig DI, Kang DH, Johnson RJ, N Engl J Med 2008 359 17 1811 1821 10.1056/NEJMra0800885 18946066
3. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Choi HK, Curhan G, Br Med J 2008 336 309 312 10.1136/bmj.39449.819271.BE (Pubitemid 351278368)
4. New therapies for gout. Crittenden DB, Pillinger MH, Annu Rev Med 2013 64 325 337 10.1146/annurev-med-080911-105830 23327525
5. Renal transport of uric acid: evolving concepts and uncertainties. Bobulescu IA, Moe OW, Adv Chronic Kidney Dis 2012 19 6 358 371 10.1053/j.ackd.2012.07.009 23089270
6. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. Hosomi A, Nakanishi T, Fujita T, Tamai I, PLoS One 2012 7 2 30456 10.1371/journal.pone.0030456 22348008
7. URAT1 mutations cause renal hypouricaemia type 1 in Iraqi Jews. Dinour D, Bahn A, Ganon L, Ron R, Geifman Holtzman O, Knecht A, Gafter U, Ruth Rachamimov R, Sela BA, Gerhard Burckhardt G, Holtzman EJ, Nephrol Dial Transplant 2011 26 7 2175 2181 10.1093/ndt/gfq722 21148271
8. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, for the EUROSPAN Consortium, et al. PLoS Genet 2009 5 6 1000504 10.1371/journal.pgen.1000504 19503597
9. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Yang Q, Köttgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, Chasman DI, Aspelund T, Eiriksdottir G, Harris TB, Launer L, Nalls M, Hernandez D, Arking DE, Boerwinkle E, Grove ML, Li M, Kao WHL, Chonchol M, Haritunians T, Li G, Lumley T, Psaty BM, Shlipak M, Hwang SJ, Larsson MG, O'Donnell CJ, Upadhyay A, van Duijn CM, Hofman A, et al. Circ Cardiovasc Genet 2010 3 6 523 530 10.1161/CIRCGENETICS.109.934455 20884846
10. Homozygous SLC2A9 mutations cause severe renal hypouricemia. Dinour D, Gray NK, Campbell S, Shu X, Sawyer L, Richardson W, Rechavi G, Amariglio N, Ganon L, Sela BA, Bahat H, Goldman M, Weissgarten J, Millar MR, Wright AF, Holtzman EJ, J Am Soc Nephrol 2010 21 1 64 72 10.1681/ASN.2009040406 19926891
11. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, Pistis G, Ruggiero D, O'Seaghdha CM, Haller T, Yang Q, Tanaka T, Johnson AD, Kutalik Z, Smith AV, Shi J, Struchalin M, Middelberg RPS, Brown MJ, Gaffo AL, Pirastu N, Li G, Hayward C, Zemunik T, Huffman J, Yengo L, Zhao JH, Demirkan A, Feitosa MF, Liu X, et al. Nat Genet 2013 45 2 145 154 23263486
12. Association between genotype and phenotype in uromodulin-associated kidney disease. Moskowitz JL, Piret SE, Lhotta K, Kitzler TM, Tashman AP, Velez E, Thakker RV, Kotanko P, Clin J Am Soc Nephrol in press
13. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Juraschek SP, Kovell LC, Miller ER III, Gelber AC, Sem Arthritis Rheumatism 2013 42 6 551 561 10.1016/j.semarthrit.2012.09.009
14. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologictherapeutic approaches to hyperuricemia. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, et al. Arthritis Care Res 2012 64 10 1431 1446 10.1002/acr.21772
15. Japanese guideline for the management of hyperuricemia and gout: Second edition. Yamanaka H, Nucleosides Nucleotides Nucleic Acids 2011 30 12 1018 1029 10.1080/15257770.2011.596496 22132951
16. Difficult-to-treat gouty arthritis. A disease warranting better management. Schlesinger N, Drugs 2011 71 11 1413 1439 10.2165/11592290- 000000000-00000 21812506
17. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Becker MAH, Ralph Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C, Arthritis Res Ther 2010 12 63 10.1186/ar2978 20370912
18. Clinical risk factors for adverse events in allopurinol users. Ryu HJ, Song R, Kim HW, Kim JH, Lee EY, Lee YJ, Song YW, Lee EB, J Clin Pharmacol 2013 53 2 211 216 10.1177/0091270012439715 23436266
19. Lesinurad (RDEA594), a novel uricosuric agent, in combination with febuxostat shows significant additive urate lowering effects in gout patients with 100% response achieved for all combination dose regimens [abstract]. Fleischmann R, Shen Z, Yeh L-T, Kerr B, Polvent E, Suster M, Hingorani V, Miner JN, Manhard K, Quart B, Ann Rheum Dis 2011 70 Suppl. 3 188 20736390
20. The gout pipeline crystallizes. Kotz J, Nature Rev Drug Discov 2012 11 6 425 426 10.1038/nrd3748
21. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Ohno I, Yamaguchi Y, Saikawa H, Uetake D, Hikita M, Okabe H, Ichida K, Hosoya T, Inter Med 2009 48 6 415 420 10.2169/internalmedicine.48.1817
22. Hyperuriemia and gout: state of the art and future perspectives. Dalbeth N, So A, Ann Rheum Dis 2010 69 10 1738 1743 10.1136/ard.2010.136218 20858623
23. Uric acid transport and disease. So A, Thorens B, J Clin Invest 2010 120 6 1791 1799 10.1172/JCI42344 20516647
24. Is there anything good in uric acid? Álvarez-Lario B, Macarrón-Vivente J, QJM 2011 104 12 1015 1024 10.1093/qjmed/hcr159 21908382
25. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ, Hypertension 2001 38 5 1101 1106 10.1161/hy1101.092839 11711505 (Pubitemid 34252813)
26. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ, Am J Physiol Renal Physiol 2002 282 6 991 F997 11997315
27. Hyperuricemia and incident hypertension: A systemic review and meta-analysis. Grayson PC, Kim SY, LaValley M, Choi HK, Arthritis Care Res 2011 63 1 102 110 10.1002/acr.20344
28. Hyperuricemia in childhood primary hypertension. Feig DI, Johnson RJ, Hypertension 2003 42 3 247 252 10.1161/01.HYP.0000085858.66548.59 12900431 (Pubitemid 37093468)
29. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. Feig DI, Soletsky B, Johnson RJ, J Am Med Assoc 2008 300 8 924 932 10.1001/jama.300.8.924
30. Uric acid reduction rectifies prehypertension in obese adolescents. Soletsky B, Feig DI, Hypertens 2012 60 5 1148 1156 10.1161/HYPERTENSIONAHA.112. 196980
31. Effect of allopurinol on blood pressure: A systematic review and meta-analysis. Agarwal V, Hans N, Messerli FH, J Clin Hypertens 2013 16 6 435 442
32. Pharmacotherapy for hyperuricemia in hypertensive patients. Gois PHF, Souza ERDM, Cochrane Library 2013 1 http://onlinelibrary.wiley.com/doi/10.1002/ 14651858.CD008652.pub2/full
33. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. Choi HK, Soriano LC, Zhang Y, Rodrigues LAG, Br Med J 2012 344 8190 10.1136/bmj.d8190
34. Hyperuricemia and the Progression of Chronic Kidney Disease: Is uric acid a marker or an independent risk factor. Nashar K, Fried LF, Adv Chronic Kidney Dis 2012 19 6 386 391 10.1053/j.ackd.2012.05.004 23089273
35. A role for uric acid in the progression of renal disease. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ, J Am Soc Nephrol 2002 13 12 2888 2897 10.1097/01.ASN.0000034910.58454.FD 12444207 (Pubitemid 35386908)
36. Uric acid and chronic kidney disease: which is chasing which? Johnson RJ, Nakagawa T, Jalal D, Sánchez Lozada LG, Kang DH, Ritz E, Nephrol Dial Transplant 2013 in press
37. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Siu YP, Leung KT, Tong MK, Kwan TH, Am J Kidney Dis 2006 47 1 51 59 10.1053/j.ajkd.2005.10.006 16377385 (Pubitemid 41828266)
38. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J, Clin J Am Soc Nephrol 2010 5 8 1388 1393 10.2215/CJN.01580210 20538833
39. Effect of allopurinol in decreasing proteinuria in Type 2 diabetic patients. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S, Iranian J Kid Dis 2010 4 2 128 132
40. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Shi Y, Chen W, Jalal D, et al. Kidney Blood Press Res 2012 35 3 153 160 10.1159/000331453 22116196
41. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin ii antagonist losartan trial. Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ, Hypertension 2011 58 1 2 7 10.1161/HYPERTENSIONAHA.111.171488 21632472
42. Gout and the risk for incident heart failure and systolic dysfunction. Krishnan E, Br Med J Open 2012 2 1 000282
43. Uric acid as a predictor of all-cause mortality in heart failure: A Meta-analysis. Tamariz L, Verma S, Congest Heart Fail 2011 17 1 25 30 10.1111/j.1751-7133.2011.00200.x 21272224
44. Hyperuricemia predicts adverse outcome in patients with heart failure. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, Kinugawa S, Yokoshiki H, Takeshita A, Tsutsui H, for the JCARE-CARD Investigators, Internat J Cardiol 2011 151 2 143 147 10.1016/j.ijcard.2010.05. 002
45. Changes in uric acid levels and allopurinol use in chronic heart failure: Association with improved survival. Gotsman I, Kern A, Lotan C, Zwas DR, J Cardiac Failure 2012 18 9 694 701 10.1016/j.cardfail.2012.06.528
46. Hyperuricemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Filippatos GS, Ahmed MI, Gladden JD, Aban IB, Love TE, Sanders PW, Pitt B, Anker SD, Ahmed A, Eur Hear J 2011 32 6 712 720 10.1093/eurheartj/ehq473
47. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Harzand A, Tamariz L, Hare JM, Congest Heart Fail 2012 18 3 179 182 10.1111/j.1751-7133.2011.00262.x 22587748
48. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering UA. George J, Carr E, Davies J, Belch JJF, Struthers A, Circulation 2006 114 23 2508 2516 10.1161/CIRCULATIONAHA.106.651117 17130343 (Pubitemid 44901524)
49. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Noman A, Ang DSC, Ogston S, Lang CC, Struthers AD, Lancet 2010 375 9732 2161 2167 10.1016/S0140-6736(10)60391-1 20542554
50. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double- blind placebo-controlled crossover preliminary study. Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S, Kinugawa T, Igawa O, Hisatome I, Shigemasa C, Anker SD, Doehner W, Circ Heart Fail 2010 3 1 73 81 10.1161/CIRCHEARTFAILURE.109.868604 19933411
51. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS, Metabolism 2006 55 10 1293 1301 10.1016/j.metabol.2006. 05.013 16979398 (Pubitemid 44354944)
52. Association between serum uric acid and development of type 2 diabetes. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H, Diabetes Care 2009 32 9 1737 1742 10.2337/dc09-0288 19549729
53. High serum uric acid as a novel risk factor for type 2 diabetes. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC, Diabetes Care 2008 31 2 361 362 17977935 (Pubitemid 351213351)
54. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML, Hypertension 2003 42 3 474 480 12953019 (Pubitemid 37237341)
55. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Kanellis J, Kang DH, Semin Nephrol 2005 25 1 39.42 15660333
56. Metabolic syndrome, diabetes, and hyperuricemia. Li C, Hsieh MC, Chang SJ, Curr Opin Rheumatol 2013 25 2 210 216 10.1097/BOR.0b013e32835d951e 23370374
57. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. Facchini F, Chen YD, Hollenbeck CB, Reaven GM, J Am Med Assoc 1991 266 21 3008 3011 10.1001/jama.1991.03470210076036
58. Effect of insulin on uric acid excretion in humans. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciaciaro D, Ferrannini E, Am J Physiol 1995 268 1 1 E5 7840165
59. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Muscelli E, Natali A, Bianchi S, Bigazzi S, Quinones Galvan AQ, Sironi AM, Frascerra S, Ciociaro D, Ferrannini E, Am J Hypertens 1996 9 8 746 752 10.1016/0895-7061(96)00098-2 8862220 (Pubitemid 26271219)
60. Mouse GLUT9: evidences for a urate uniporter. Bibert S, Hess SK, Firsov D, Thorens B, Geering K, Horisberger JD, Bonny O, Am J Physiol Renal Physiol 2009 297 3 612 619 10.1152/ajprenal.00139.2009 19587147
61. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H, J Biol Chem 2008 283 5 26834 26838 18701466
62. Human vascular smooth muscle cells express a urate transporter. Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, Johnson RJ, J Am Soc Nephrol 2006 17 7 1791 1795 10.1681/ASN.2006030264 16775029 (Pubitemid 44036162)
63. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase mediated oxidative/nitrosative stress. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ, Am J Physiol Cell Physiol 2007 293 2 584 596 10.1152/ajpcell. 00600.2006 17428837 (Pubitemid 47235197)
64. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Shafiu M, Johnson RJ, Turner ST, Langaee T, Gong Y, Chapman AB, Gums JG, Johnson JA, Kidney Blood Press Res 2012 35 6 477 482 10.1159/000337370 22688828
65. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C, Johnson RJ, Sautin YY, Diabetes 2011 60 4 1258 1269 10.2337/db10-0916 21346177
66. Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Brymora A, Flisinski M, Johnson RJ, Goszka G, Stefanska Manitius J, Nephrol Dial Transplant 2012 27 2 608 612 10.1093/ndt/gfr223 21613382
67. Uric acid best predicts metabolically unhealthy obesity with increased cardiovascular risk in youth and adults. Mangge H, Zelzer S, Puerstner P, Schnedl WJ, Reeves G, Postolache TT, Weghuber D, Obesity 2013 21 1 71 E77 10.1002/oby.20061 23401248
68. Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Petta S, Camma CD, Cabibi D, Di Marco V, Craxi A, Aliment Pharmacol Therapeut 2011 24 7 757 766
69. Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. Petta S, Macaluso SF, Cammà C, Di Marco V, Cabibi D, Craxì A, Liver Int 2012 32 9 1443 1450 10.1111/j.1478-3231.2012.02842.x 22764879
70. Beware of the low urine pH-the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes. Bell DSH, Diabetes Obes Metab 2012 14 4 299 303 10.1111/j.1463-1326.2011.01519.x 21992452
71. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Culleton BF, Larson MG, Kannel WB, Ann Intern Med 1999 131 1 7 13 10.7326/0003-4819-131-1-199907060-00003 10391820 (Pubitemid 29310011)
72. Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA, Arthritis Rheum 2010 62 2 170 180
73. Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA, Arthritis Rheum 2009 61 7 885 892 10.1002/art.24612 19565556
74. Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Rablink TJ, Luscher TF, Arterioscler Thromb Vasc Biol 2006 26 2 267 271 16293798 (Pubitemid 43732184)
75. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR, Cardiovasc Therap 2012 30 4 217 226 10.1111/j.1755-5922. 2011.00277.x
76. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. Rajendra NS, Ireland S, George J, Belch JJF, Lang CC, Struthers AD, J Am Coll Cardiol 2011 58 8 820 828 10.1016/j.jacc.2010.12.052 21835317
77. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Dogan A, Yarlioglues M, Kaya MG, Karadag Z, Dogan S, Ardic I, Dogdu O, Kilinc Y, Zencir C, Akpek M, Ozdogru I, Oguzhan Kalay AN, Blood Press 2011 20 3 182 187 10.3109/08037051.2010.538977 21133824
78. Xanthine-oxidase inhibitors and statins in chronic heart failure: Effects on vascular and functional parameters. Greig D, Alcaino H, Castro PF, Garcia L, Verdejo HE, Navarro M, López R, Mellado R, Tapia F, Gabrielli LA, Nogerol C, Chiong M, Godoy I, Lavandero S, J Heart Lung Transpl 2011 30 4 408 413 10.1016/j.healun.2010.10.003
79. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Waring WS, McKnight JA, Webb DJ, Diabetologia 2007 50 12 2572 2579 10.1007/s00125-007-0817-7 17928991 (Pubitemid 350060638)